 Title: Treatment of ocular disorders

FIELD OF THE INVENTION

The invention relates to a method for treating ocular disorders, in particular to a method for treating retinal edema, and especially macular edema.

BACKGROUND OF THE INVENTION

Retinal edema is identified as an abnormal accumulation of fluid in retinal cells. Macular edema is identified as intraretinal fluid in the macular region. This phenomenon is often a complication of a variety of diseases, including ocular diseases such as uveitis and may result in a decreased visual acuity. In fact, cystoid macular edema is the most important cause for visual impairment in uveitis.

Retinal edema evolves from leaking retinal vessels of a deficient aqueous pump function by the retinal pigment epithelium cells. In order to diminish the edema either the leakage should be stopped or the pump function should be regulated.

Retinal edema may result from a breakdown of the blood retinal barrier resulting in leakage from retinal capillaries or by a reduction of the active transport of fluid from the retina towards the choroid, or both.

Clinically important sequelae of retinal, and in particular macular, edema are loss of visual acuity and secondary structural changes of the retinal anatomy with photoreceptor loss. Until now, the main approach in treatment of retinal edema is treatment of the underlying disease, when possible.

Thus, immune suppressive therapy in uveitis may lead to inhibition of the inflammation and secondary to diminishing of macular edema. Symptomatic treatment of retinal edema includes treatment with various pharmaceuticals such as diclofenac eye drops, peribulbar injections of betamethasone, acetazolamide and enalapril and prostaglandin inhibitors.

Although in a number of cases, there is a relief of the discomfort caused or even a cure of the edema, there is a need for an alternative method of treatment. In addition, there are types of retinal edema which do not respond to any
5 of the known treatments, e.g. idiopathic cystoid macular edema.

It is an object of the present invention to find such a treatment.

It is a further object of the present invention to
10 find new treatments for retinal edema that could not be treated successfully until now.

SUMMARY OF THE INVENTION

15 In accordance to the present invention, it has been found that the objects of the invention can be achieved by the administration to a patient of compounds that bind to at least one somatostatin receptor, such as hSST-1, hSST 2, hSST-3, hSST-4 or hSST-5, and preferably to at least the
20 hSST-2 receptor, and more preferably to the hSST-2a receptor.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, it has been
25 found that a beneficial effect is obtained when compounds that bind to at least one somatostatin receptor are administered to patients suffering from retinal edema. More in particular, if patients suffering from cystoid macular edema are treated with compounds that bind to somatostatin
30 receptors, such as hSST-1, hSST-2, hSST-3, hSST-4 or hSST-5, it was found that the edema diminished or even disappeared. Further inflammation reactions decreased.

Preferably, said compound binds to somatostatin receptors in the nanomolar range.

In a preferred embodiment of the method of the invention, the said compound binds to a hSST-2 receptor, most preferably to a hSST-2a receptor.

The ocular disorders to be treated are generally caused by retinal edema, more in particular by macular edema, and particularly by cystoid macular edema (CME). Further it has been found that idiopathic CME also diminishes.

In accordance with the present invention it has been found that the somatostatin receptor binding compounds in the method of treatment of the present invention have a number of beneficial effects. These effects can be subdivided in three categories.

Category (1) is associated with the stopping of leakage in existing and new ocular vessels. This effect is relevant to e.g. the treatment of macular edema, accumulation of subretinal fluid, exudates in age related macular degeneration (AMD) and exudates in diabetic retinopathy (DR).

Category (2) deals with the restoration and/or regulation of retinal pigment epithelium function with respect to fluid and ion transport. Typical examples are selected from AMD exudates, DR exudates, central serous chorio-retinopathy (CSCR), macular edema and accumulation of subretinal fluid.

In Category (3) neovascularization in AMD and DR is inhibited. A typical example is selected from subretinal neovascularization.

Utility preference is given to category (1) and (2); even more preferred is category (1).

Accordingly, the present invention relates to a method of treating an ocular disorder of category (1), (2) and (3), which method comprises the administration of a somatostatin analogue to a patient.

Suitable compounds to be used in the method of the present invention belong to the naturally occurring class of the somatostatins. Somatostatin is a neuropeptide which constitutes a multi gene peptide family with two principal

- bioactive products, somatostatin-14 and somatostatin-28. It acts on multiple organs including the brain gut, endocrine glands, pancreas, kidneys and the immune system (Reichlin S. Somatostatin (first of two parts). N Engl J Med 1983;309:1495-501, Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983;309:1555-63, Krulich I, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968;83:783-90, Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemín R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:779, Lucey MR. Endogenous somatostatin and the gut. Gut 1986;27:457-67, Mehler PS, Sussman AL, Maman A, Leitner JW, Sussman KE. Role of insulin secretagogues in the regulation of somatostatin binding by isolated rat islets. J Clin Invest 1980;66:1334-8). Somatostatin binds to 5 types of G-protein coupled transmembrane receptors (sst) (Schönbrunn A, Tashjian H Jr. Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J Biol Chem 1978;253:6472-83. Reubi JC, Kvoils LK, Krenning EP, Lamberts SWJ. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990;39 Suppl 2:78-81. Patel YC, Greenwood MT, warczyńska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994;198:605-12). Somatostatin analogues can be used as well.


More in general, the somatostatin class is a known class of small peptides comprising the naturally occurring somatostatin-14 and analogues having somatostatin related activity, e.g. as disclosed by A.S. Dutta in Small Peptides, Vol. 19, Elsevier (1993). By the term a "somatostatin peptide" or "a somatostatin analogue" as used herein is meant any straight or cyclic polypeptide having a structure based on that of the naturally occurring somatostatin-14 wherein

one or more amino acid units have been omitted and/or replaced by one or more other amino radical(s) and/or wherein one or more functional groups have been replaced by one or more other functional groups and/or one or more groups have been replaced by one or several other isosteric groups. In general, the term covers all modified derivatives of the native somatostatin which exhibit a somatostatin related activity e.g., that bind to at least one somatostatin receptor (hSST-1, hSST-2, hSST-3, hSST-4 or hSST-5), preferably to at least the hSST-2 receptor.

The terms a somatostatin, a somatostatin peptide and a somatostatin analogue are used within this disclosure as synonyms.

Cyclic, bridged cyclic and straight-chain somatostatin analogues or derivatives are known and have been described together with processes for their production e.g. in US-A-4,310,518, US-A-4,235,886 and EP-A-0 001 296, the contents thereof, in particular with respect to the compounds, being incorporated herein by reference.

Preferred somatostatin analogues are e.g. compounds of formula (I).



wherein


A is C₁₋₁₂alkyl, C₆₋₁₀phenylalkyl or a group of formula RCO-, whereby

- (i) R is hydrogen, C₁₋₁₁alkyl, phenyl or C₇₋₁₀phenylalkyl, or
 (ii) RCO- is

- a) a D-phenylalanine residue optionally ring-substituted by halogen NO₂, NH₂, OH, C₁₋₃alkyl and/or C₁₋₃alkoxy; or

- b) the residue of a natural or a synthetic α -amino-acid other than defined under a) above, or of a corresponding D amino acid, or
- 5 c) a dipeptide residue in which the individual amino acid residues are the same or different and are selected from those defined under a) and/or b) above,
- 10 the α -amino group of amino acid residues a) and b) and the N-terminal amino group of dipeptide residues c) being optionally mono- or di- C_{1-12} alkylated or substituted by C_{1-12} alkanoyl;
- A is hydrogen or C_{1-12} alkyl.
- 15 Y_1 and Y_2 represent together a direct bond or each of the Y_1 and Y_2 is hydrogen
- B is -Phe- optionally ring-substituted by halogen, NO_2 , NH_2 , OH, C_{1-12} alkyl and/or C_{1-12} alkoxy (including pentafluoroalanine), naphthylalanine or
- 20 pyridylalanine.
- C is (L)-Trp- or (D)-Trp- optionally α -N-methylated and optionally benzene-ring-substituted by halogen, NO_2 ,
- 25 NH_2 , OH C_{1-12} alkyl and/or C_{1-12} alkoxy.
- D is Lys, 4-aminocyclohexylAla or 4-aminocyclohexylGly
- 30 E is Thr, Ser, Val, Tyr, ILe, Leu or an aminobutyric or aminoisobutyric acid residue
- G is a group of formula: $-COOR_{10}$, $-CH_2OR_{10}$, $-CONR_{11}R_{12}$ or

7



wherein

- 5 R_1 is hydrogen or C_{1-4} alkyl,
 R_{10} is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester,
 R_{11} is hydrogen, C_{1-4} alkyl, phenyl or C_{7-10} phenyl-alkyl,
 R_{12} is hydrogen, C_{1-4} alkyl or a group of formula $-CH(R_{13})-$
 10 X_1 ,
 R_{13} is CH_2CH_3 , $-(CH_2)_2-OH$, $-(CH_2)_3-OH$, or $-CH(CH_3)OH$ or represents the substituent attached to the α -carbon atom of a natural or synthetic α -amino acid (including hydrogen) and
 15 X_1 is a group of formula $-COOR_4$, $-CH_2OR_5$ or $-CO-NR_6R_7$

wherein

- R_4 and R_5 have the meanings given above,
 R_6 is hydrogen or C_{1-4} alkyl and
 20 R_7 is hydrogen, C_{1-4} alkyl, phenyl or C_{7-10} phenylalkyl, and
 R_8 is hydrogen or hydroxy,

with the proviso that

when R_{12} is $-CH(R_{13})-X_1$ then R_{13} hydrogen or methyl.

25

wherein the residues B, D and E have the L-configuration, and the residues in the 2- and 7-position each independently have the (L)- or (D)-configuration,

- 30 in free form or in pharmaceutically acceptable salt or complex form.

Individual compounds of formula I suitable in accordance with the present invention are the following somatostatin

- 35 analogues:

10079934-0314003

- a. (D) Phe-Cys-Phe- (D) Trp-Lys-Thr-Cys-Tyr-ol
also known as octreotide
- 5 b. (D) Phe-Cys-Tyr- (D) Trp-Lys-Val-Cys-ThrNH₂
- c. (D) Phe-Cys-Tyr- (D) Trp-Lys-Val-Cys-TrpNH₂
also known as vapreotide
- 10 d. (D) Trp-Cys-Phe- (D) Trp-Lys-Thr-Cys-ThrNH₂
- e. (D) Phe-Cys-Phe- (D) Trp-Lys-Thr-Cys-ThrNH₂
- 15 f. 3-(2-(Naphthyl) - (D) Ala-Cys-Tyr- (D) Trp-Lys-Val-Cys-ThrNH₂
also known as lanreotide
- g. (D) Phe-Cys-Tyr- (D) Trp-Lys-Val-Cys-β-Nal-NH₂
- 20 h. 3-(2-(Naphthyl) - (D) Ala-Cys-Tyr- (D) Trp-Lys-Val-Cys-β-Nal-NH₂
- i. (D) Phe-Cys-β-Nal- (D) Trp-Lys-Val-Cys-Thr-NH₂
- 25 j. (D) Phe-Cys-Tyr- (D) Trp-Lys-Leu-Cys-Thr-NH₂
- k. (D) Phe-Cys-Tyr- (D) Trp-Lys-Cys-Thr-NH₂

More preferred compounds of formula (I) are compounds (a) -
30 (k).

A highly preferred compound of formula (I) is octreotide.

Compounds of formula (I) may exist e.g. in free form, salt
25 form or in the form of complexes thereof. Acid addition salts
may be formed with e.g. organic acids, polymeric acids and

inorganic acids. Such acid addition salt forms include e.g. the hydrochlorides and acetates. Complexes are e.g. formed from compounds of the invention on addition of inorganic substances, e.g. inorganic salts or hydroxides such as Ca- and Zn-salts, and/or and addition of polymeric organic substances.

According to the invention, the compound binding to somatostatin receptor is preferably administered in the form of a pharmaceutical composition, by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets, capsules, drink solutions, emulsions or microemulsion preconcentrates, nasally, pulmonary (by inhalation), parenterally, e.g. in the form of injectable solutions or suspensions, or topically. The compound is preferably administered parenterally, typically subcutaneously, e.g. by injection and/or infusion

In a further aspect, the compound capable of binding to a somatostatin is administered topically to an individual, typically in the form of an ophthalmic liquid preparation (eye drop), in the form of a gel and/or in the form of an ointment.

The compound capable of binding to a somatostatin receptor may also be administered locally e.g. intravitreally and peribulbally.

The amount administered is determined taking into account various factors such as the etiology and severity of the disease, and the patient's condition. A somatostatin analogue may be administered, e.g. subcutaneously in a dosage range of about 100 µg to 10 mg per day as a single dose or in divided doses. Thus octreotide may be administered at a dose of from 0.2 mg to 10 mg twice or three times daily. When administered as a slow release form, such formulation may comprise the somatostatin peptide in a concentration from 2.0 to 10% by weight. The release period of such a formulation may be from 1 week to about 2 months.

THE BEST MODE

The best results up to now have been obtained by
5 using octreotide as the somatostatin receptor binding
compound. These results are elaborated herein-below:

The present invention will be further illustrated by
the following non-limiting examples.

10

EXAMPLES

Treatment of cystoid macular edema

A 21 year old man was found to have moderate color-
15 vision defects at routine examination. One year later, he
noticed blurred vision. His visual acuity was 20/50 in the
right eye and 20/40 in the left eye (by Snellen chart).
Because he had bilateral cystoid macular edema, he was
treated with diclofenac eye drops, peribulbar injections of
20 betamethasone, acetazolamide, and enalapril without
beneficial effect on the edema or visual acuity. His visual
acuity slowly deteriorated in the subsequent years. When we
examined the patient three years after he first noted
blurring of his vision, his visual acuity was 20/100 in each
25 eye, the macular regions showed large cystoid lesions and
there was no intraocular inflammation (anterior chamber flare
or cells, vitreous cells, vascular sheathing, exudates, or
pars planitis). He had no family history of macular edema.
Fluorescein angiography showed accumulation of dye in the
30 cystoid lesions. Because the previous therapy had failed to
correct the problem, the patient was treated with octreotide.
100 µg subcutaneously three times daily, after he gave
informed consent. He noted visual improvement after six
weeks, and when tested after eight weeks his visual acuity
35 was 20/40 in the right eye and 20/50 in the left eye.
Ophthalmoscopically, the cysts had dried. The injections were

stopped four weeks later, because there was no further improvement.

Within two weeks the patient noticed increased reading difficulty, his visual acuity was 10/50 in each eye, and some fluid was observed ophthalmoscopically. Treatment with 100 µg of octreotide subcutaneously once daily was resumed. Three months later the patient's visual acuity was 20/40 in each eye; fluorescein angiography showed some focal fluorescein leakage. He stopped treatment a second time; after four weeks his visual acuity was 20/70 in the right eye and 20/50 in the left eye. Octreotide therapy was resumed, and four weeks later his visual acuity was 20/40 in each eye. The patient had no side effects from the treatment. The decreased macular edema during treatment with octreotide, the recurrence after stopping treatment, and the response after restarting it suggest that the changes were due to octreotide.

Example 2

Patients

5 Patients were treated in accordance to the
declaration of Helsinki. In this study, 10 consecutive
patients from the Department of Ophthalmology, Erasmus
University Medical Center, and the Eye Hospital Rotterdam,
were selected because of refractory CME due to chronic
10 uveitis. Since CME in uveitis can be influenced in time by
multiple factors, only patients suffering from macular edema
for more than 6 months were included, regardless of their
immune suppressive treatment. Six patients had bilateral CME
and four patients unilateral. Three patients with pars
15 planitis needed no treatment for their inflammation but still
had marked CME. Fluorescein angiography was performed within
one week before starting octreotide treatment. Octreotide
therapy was given after informed consent had been obtained.
Dosage was started with 100 µg subcutaneously, on the first
20 day, two times 100 µg on the second day and three times 100
µg from the third day onwards. When possible, the long-acting
repeatable (LAR) formulation was prescribed in a dosage of 20
mg per 4 weeks intramuscularly, which became available during
the studies. The dose of patient 3, a 15 year old boy, was
25 adjusted for his age to 10 mg per month (im). Immune
suppressive treatment was adjusted as based on inflammatory
activity. Visual acuity was measured after 2, 4, and 12 weeks
of treatment. Fluorescein angiography was repeated after
three months of treatment.

30

Clinical effects of octreotide

All patients concluded three months therapy. In none
of the patients visual acuity or inflammation activity
35 deteriorated. Four patients showed a decreased inflammation,
leading to a tapered immunosuppressive therapy.

10079931-0314002

13

By stereoscopic examination the CME had dissolved in 5 eyes and diminished in a further 11 eyes. Fluorescien angiographic macular edema was clearly diminished in only 3 eyes, was diminished but still visible in 9 eyes, and was unaltered in 3 eyes. In one eye the angiogram could not be interpreted because of poor quality. No side effects were observed, except diarrhoea during the first days of treatment in 4 patients. Ocular hypertension was measured in one patient at week 4, which was treated with timolol.

Example 3

Immuno histopathology

For histopathology 3 human eyes were obtained after enucleation. Two eyes were enucleated because of malignant melanoma and one because of a painful blind eye with corneal ulceration and perforation, showing extensive CME. In order to investigate the expression of somatostatin receptors, immunohistochemical analysis was performed with rabbit polyclonal anti-somatostatin receptor subtype -1 and -2a antibodies (anti-*sst₁* and anti-*sst_{2a}*) (Dournaud P, Cu YZ, Schönbrunn A, Mazella J, Tannenbaum GS, Beauder A. Localization of the somatostatin receptor *sst2A* in rat brain using a specific antipeptide antibody. *J Neurosci* 1996;16:4468-78). Specifically of the antibodies has been demonstrated before by Western Blot analysis. Frozen tissue sections (5µm) mounted on uncoated glass slides were dried, fixed in 10% formalin, rinsed in PBS and preincubated for 15 min. at room temperature (RT) with 10% normal goat serum in PBS/5%BSA. Incubation with anti-*sst₁* and anti-*sst_{2a}* antibodies (dilution 1:1000) was carried out overnight at 4°C. The sections were rinsed twice in PBS and incubated for 30 min. at RT with alkaline phosphatase-conjugated goat-anti-rabbit immunoglobulin (GoRig-AP, D0487, Dakopatts, Glostrup, Denmark) diluted 1:50 in PBS/5%BSA containing 2% normal human

serum. Hereafter, the sections were rinsed twice with PBS. Alkaline phosphatase activity was revealed by new fuchsin as the chromogen in the presence of levamisole to block endogenous alkaline phosphatase activity, followed by hematoxylin staining. Controls for immunohistochemistry included: 1) omission of the primary antibody, 2) incubation with normal rabbit serum, 3) pre-absorption of the antiserum with the immunizing peptide.

10 Immunohistochemistry

The polyclonal antibodies against sst_1 and sst_{2A} are specific for human somatostatin receptor 1 and 2a respectively. A red chromogen was used to differentiate from the brown pigment in the retinal pigment epithelium (RPE).

Sst_1 positive staining was noted in ganglion cells and amacrine cells of the inner nuclear layer, and the photoreceptors. Sst_{2A} was found in the inner and outer plexiform layer, the inner and outer nuclear layer, and the apical membranous part of the retinal pigment epithelium. In the retina with CME similar staining for sst_{2A} was observed.